Repligen Corporation announced Wednesday that it will acquire BioLife Solutions in a cash-and-stock deal valued at approximately 1.5 billion dollars, marking a significant expansion into the fast-growing cell therapy market.

The acquisition gives Repligen, a leading bioprocessing equipment provider, access to BioLife's market-leading biopreservation media technology and high-margin consumables business, positioning the combined company as a major force in the cell therapy manufacturing space.

Deal Structure and Valuation

Under the terms of the agreement, BioLife shareholders will receive 11.25 dollars in cash and 0.1442 shares of Repligen common stock for each BioLife share, valuing the cell therapy tools supplier at 31 dollars per share.

The offer represents a premium of approximately 6.2 percent to BioLife's previous closing price. The transaction breaks down as 64 percent Repligen stock and 36 percent cash.

The boards of both companies have unanimously approved the merger, which is expected to close in the fourth quarter of 2026, pending regulatory approvals and BioLife shareholder approval.

Strategic Rationale

The acquisition accelerates Repligen's position in the cell therapy market, one of the fastest-growing segments in bioprocessing. BioLife's technology is used to preserve cells throughout the manufacturing process and supply chain, a critical capability as cell-based therapies move from research to commercial production.

Cell therapies, including CAR-T treatments and other personalized medicines, require specialized tools to maintain cell viability during manufacturing, storage, and transport. BioLife's biopreservation media is used by pharmaceutical companies worldwide to protect these sensitive biological products.

Repligen expects the acquisition to generate at least 20 million dollars in cost savings within the first year after closing by eliminating overlapping operations and improving efficiency. The deal is also expected to be immediately accretive to earnings.

Market Context

The acquisition comes amid a broader consolidation wave in the life sciences tools sector. Just last month, German drugmaker Merck KGaA announced an 11.3 billion dollar deal to acquire Bio-Techne, underscoring the intense interest in companies that provide tools and services for drug development.

The timing is also notable given improving fundamentals in the bioprocessing industry. Danaher, a larger peer in the space, signaled on Tuesday that demand for bioprocessing products is recovering after a broader slowdown in research spending and customer inventory adjustments over the past two years.

Biotech and pharmaceutical companies are ramping up spending again, creating a favorable backdrop for companies like Repligen that provide essential manufacturing equipment and consumables.

BioLife's Business

BioLife Solutions, headquartered in Bothell, Washington, has built a leading position in biopreservation media and cell-processing tools. The company's products are used in the production of cell and gene therapies, tissue engineering applications, and bio-banking operations.

Its recurring revenue model, driven by high-margin consumables that customers must continually repurchase, makes it an attractive acquisition target. The company has benefited from the rapid growth of cell therapy approvals and the expanding pipeline of advanced therapies in clinical development.

What It Means for Shareholders

For BioLife shareholders, the deal offers a modest premium and exposure to Repligen's larger platform. The stock component means shareholders will participate in the combined company's future growth.

For Repligen shareholders, the acquisition represents a strategic bet on cell therapy manufacturing, adding capabilities that complement the company's existing filtration, chromatography, and fluid management businesses.

The 1.5 billion dollar price tag makes this one of the larger bioprocessing deals of 2026 and reflects the premium valuations that cell therapy assets continue to command in the current market.